急性細菌性皮膚・皮膚構造感染症市場：感染タイプ、疾患カテゴリー、投与経路、流通チャネル別-世界予測2025～2030年

急性細菌性皮膚・皮膚構造感染症市場は、2023年に105億2,000万米ドルと評価され、2024年には113億5,000万米ドルに達すると予測され、CAGR 8.63％で成長し、2030年には187億9,000万米ドルに達すると予測されています。

急性細菌性皮膚・皮膚構造感染症（ABSSSI）には、皮膚やその下の組織への深刻な細菌侵入が含まれ、蜂巣炎、創傷感染、膿瘍などの病態が含まれます。これらの感染症は急速に進行し、合併症を引き起こす可能性があるため、迅速かつ効果的な医療介入を必要とします。ABSSSIは医療において重要な役割を担っており、先進的な抗生物質や治療法の必要性を高めています。このような感染症の増加により、革新的なソリューションの必要性が高まる一方、その治療は主に病院、クリニック、外来手術センターで行われています。市場力学は、薬剤耐性菌の発生率の増加、医療の進歩、新しい治療法に対する意識の高まりといった要因によって推進されています。新たな抗生物質に対する需要の高まりや、より優れた診断ツールの必要性からビジネス機会が生まれ、より迅速で正確な診断技術や次世代抗菌薬の開発に大きな可能性があります。こうした機会を捉えるための推奨事項としては、新規抗菌薬の研究開発への投資、バイオテクノロジー企業との戦略的パートナーシップの形成、迅速診断のための最先端技術の活用などが挙げられます。しかし、市場は厳しい規制経路、高い薬剤開発コスト、抗生物質治療に伴う潜在的な副作用などの制約に直面しており、これが成長を鈍らせる可能性があります。耐性菌対策のための厳格な抗生物質管理プログラムが、市場浸透をさらに複雑にしています。最良の技術革新セグメントは、併用療法の開発と、耐性問題の少ない天然または合成の代替薬の探索にあります。画期的な解決策を推進するためには、製薬企業と研究機関の協力が不可欠であることを調査は示唆しています。市場は競争的であり、継続的な研究努力、変化する規制状況、費用対効果の高い解決策への需要が特徴です。全体として、ABSSSIのアンメットニーズに対応するためには技術革新が不可欠であり、企業はこの進化する市場で成功するために、規制遵守、経済的実現可能性、効果的な治療結果のバランスをとる必要があります。

市場力学：急速に進化する急性細菌性皮膚・皮膚構造感染症市場の主要市場洞察を公開

急性細菌性皮膚・皮膚構造感染症市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 細菌性皮膚感染症の流行と事例の増加
  • 皮膚トラブルに対する人々の意識の高まり
  • 皮膚科センターやクリニックの増加
• 市場抑制要因
  • ABSSSI治療に伴う健康への悪影響
• 市場機会
  • 新薬開発のための継続的な研究開発活動
  • 臨床当局による規制承認の急増
• 市場課題
  • 標準プロトコルの欠如と誤った治療管理

ポーターのファイブフォース：急性細菌性皮膚・皮膚構造感染症市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：急性細菌性皮膚・皮膚構造感染症市場における外部からの影響の把握

外部マクロ環境要因は、急性細菌性皮膚・皮膚構造感染症市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：急性細菌性皮膚・皮膚構造感染症市場における競合情勢の把握

急性細菌性皮膚・皮膚構造感染症市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：急性細菌性皮膚・皮膚構造感染症市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、急性細菌性皮膚・皮膚構造感染症市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：急性細菌性皮膚・皮膚構造感染症市場における成功への道筋を描く

急性細菌性皮膚・皮膚構造感染症市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 細菌性皮膚感染症の罹患率と症例の増加
    • 皮膚の問題に対する人々の意識を高める
    • 皮膚科センターとクリニック数の増加
  • 抑制要因
    • ABSSSI薬に関連する健康への悪影響
  • 機会
    • 新薬開発に向けた研究開発活動の継続
    • 臨床当局からの規制承認の急増
  • 課題
    • 標準的なプロトコルの欠如と不適切な治療管理
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 急性細菌性皮膚・皮膚構造感染症市場：感染タイプ別

• イントロダクション
• 地域社会で発生したABSSI
• 院内感染性ABSSI

第7章 急性細菌性皮膚・皮膚構造感染症市場：疾患カテゴリー別

• イントロダクション
• 非化膿性
• 化膿性

第8章 急性細菌性皮膚・皮膚構造感染症市場：投与経路別

• イントロダクション
• 経口
• 非経口
• 局所

第9章 急性細菌性皮膚・皮膚構造感染症市場：流通チャネル別

• イントロダクション
• 病院薬局
• オンライン薬局
• 小売薬局

第10章 南北アメリカの急性細菌性皮膚・皮膚構造感染症市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋の急性細菌性皮膚・皮膚構造感染症市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの急性細菌性皮膚・皮膚構造感染症市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbvie, Inc.
• Accord Healthcare Limited
• Amneal Pharmaceuticals, Inc.
• Aurobindo Pharma Limited
• Basilea Pharmaceutica Ltd
• BiVictriX Therapeutics PLC
• Cadila Pharmaceuticals Limited
• Cumberland Pharmaceuticals Inc.
• Debiopharm SA
• Destiny Pharma PLC
• Fresenius SE & Co. KGaA
• GlaxoSmithKline PLC
• Glenmark Pharmaceuticals Limited
• Innovation Pharmaceuticals Inc.
• Intas Pharmaceuticals Ltd.
• KBP Biosciences Co., Ltd.
• Melinta Therapeutics, LLC
• Merck & Co, Inc
• MicuRx Pharmaceuticals, Inc.
• Novartis International AG
• Paratek Pharmaceuticals, Inc.
• Pfizer Inc.
• Sun Pharmaceutical Industries Limited
• Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET RESEARCH PROCESS
• FIGURE 2. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET DYNAMICS
• TABLE 7. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COMMUNITY-ACQUIRED ABSSI, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY HOSPITAL ACQUIRED ABSSI, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY NONPURULENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PURULENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 34. CANADA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 35. CANADA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 36. CANADA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 37. CANADA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 56. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 57. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 58. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 59. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 60. INDIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 61. INDIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 62. INDIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 63. INDIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. INDONESIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. JAPAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. MALAYSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. PHILIPPINES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. SINGAPORE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. SOUTH KOREA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. TAIWAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. THAILAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. VIETNAM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 100. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 105. DENMARK ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 109. EGYPT ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. FINLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 117. FRANCE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 121. GERMANY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 125. ISRAEL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 129. ITALY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 130. ITALY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 131. ITALY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 132. ITALY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 133. NETHERLANDS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. NIGERIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 141. NORWAY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 145. POLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 146. POLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 147. POLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 148. POLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 149. QATAR ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 150. QATAR ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 151. QATAR ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 152. QATAR ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 153. RUSSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 157. SAUDI ARABIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 161. SOUTH AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 165. SPAIN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 169. SWEDEN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 173. SWITZERLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 177. TURKEY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 181. UNITED ARAB EMIRATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 185. UNITED KINGDOM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 189. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 190. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET, FPNV POSITIONING MATRIX, 2023

The Acute Bacterial Skin & Skin Structure Infection Market was valued at USD 10.52 billion in 2023, expected to reach USD 11.35 billion in 2024, and is projected to grow at a CAGR of 8.63%, to USD 18.79 billion by 2030.

Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) involve serious bacterial invasion of skin and its underlying tissues, encompassing conditions like cellulitis, wound infections, and abscesses. These infections are critical due to their rapid progression and potential complications, demanding prompt and effective medical intervention. ABSSSIs hold crucial application in healthcare, driving the need for advanced antibiotics and therapies. Rising incidences of such infections fuel the necessity for innovative solutions, while their treatment primarily resides within hospitals, clinics, and ambulatory surgical centers. Market dynamics are propelled by factors like increasing incidence of drug-resistant bacteria, healthcare advancements, and heightened awareness around new treatment modalities. Opportunities arise from the growing demand for new antibiotics and the need for better diagnostic tools, with significant potential in developing faster and more accurate diagnostic technologies and next-generation antimicrobials. Recommendations for capturing these opportunities include investing in R&D for novel antimicrobial drugs, forming strategic partnerships with biotech firms, and leveraging cutting-edge technology for rapid diagnostics. However, the market faces limitations such as stringent regulatory pathways, high costs of drug development, and potential side effects associated with antibiotic treatments, which could dampen growth. Strict antibiotic stewardship programs to combat resistance further complicate market penetration. The best innovation areas lie in developing combination therapies and exploring natural or synthetic alternatives with fewer resistance issues. Insights suggest that collaborations between pharmaceutical companies and research institutions are essential to drive groundbreaking solutions. The market is competitive, characterized by ongoing research efforts, revolving regulatory landscape, and demand for cost-effective solutions. Overall, innovation will be crucial in addressing unmet needs in ABSSSIs, as companies need to balance between regulatory compliance, economic feasibility, and effective therapeutic outcomes to succeed in this evolving market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Acute Bacterial Skin & Skin Structure Infection Market

The Acute Bacterial Skin & Skin Structure Infection Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence and cases of bacterial skin infections
  • Increasing people awareness about skin problems
  • Growth in number of dermatology centers and clinics
• Market Restraints
  • Associated adverse health impacts of ABSSSI drugs
• Market Opportunities
  • Ongoing R&D activities for development of novel drugs
  • Surge in regulatory approvals from clinical authorities
• Market Challenges
  • Lack of standard protocols and mismanaged treatments

Porter's Five Forces: A Strategic Tool for Navigating the Acute Bacterial Skin & Skin Structure Infection Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Acute Bacterial Skin & Skin Structure Infection Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Acute Bacterial Skin & Skin Structure Infection Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Acute Bacterial Skin & Skin Structure Infection Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Acute Bacterial Skin & Skin Structure Infection Market

A detailed market share analysis in the Acute Bacterial Skin & Skin Structure Infection Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Acute Bacterial Skin & Skin Structure Infection Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Acute Bacterial Skin & Skin Structure Infection Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Acute Bacterial Skin & Skin Structure Infection Market

A strategic analysis of the Acute Bacterial Skin & Skin Structure Infection Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Acute Bacterial Skin & Skin Structure Infection Market, highlighting leading vendors and their innovative profiles. These include Abbvie, Inc., Accord Healthcare Limited, Amneal Pharmaceuticals, Inc., Aurobindo Pharma Limited, Basilea Pharmaceutica Ltd, BiVictriX Therapeutics PLC, Cadila Pharmaceuticals Limited, Cumberland Pharmaceuticals Inc., Debiopharm SA, Destiny Pharma PLC, Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Innovation Pharmaceuticals Inc., Intas Pharmaceuticals Ltd., KBP Biosciences Co., Ltd., Melinta Therapeutics, LLC, Merck & Co, Inc, MicuRx Pharmaceuticals, Inc., Novartis International AG, Paratek Pharmaceuticals, Inc., Pfizer Inc., Sun Pharmaceutical Industries Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Acute Bacterial Skin & Skin Structure Infection Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Infection Type, market is studied across Community-Acquired ABSSI and Hospital Acquired ABSSI.
• Based on Disease Category, market is studied across Nonpurulent and Purulent.
• Based on Route of Administration, market is studied across Oral, Parenteral, and Topical.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence and cases of bacterial skin infections
    • 5.1.1.2. Increasing people awareness about skin problems
    • 5.1.1.3. Growth in number of dermatology centers and clinics
  • 5.1.2. Restraints
    • 5.1.2.1. Associated adverse health impacts of ABSSSI drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing R&D activities for development of novel drugs
    • 5.1.3.2. Surge in regulatory approvals from clinical authorities
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of standard protocols and mismanaged treatments
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Acute Bacterial Skin & Skin Structure Infection Market, by Infection Type

• 6.1. Introduction
• 6.2. Community-Acquired ABSSI
• 6.3. Hospital Acquired ABSSI

7. Acute Bacterial Skin & Skin Structure Infection Market, by Disease Category

• 7.1. Introduction
• 7.2. Nonpurulent
• 7.3. Purulent

8. Acute Bacterial Skin & Skin Structure Infection Market, by Route of Administration

• 8.1. Introduction
• 8.2. Oral
• 8.3. Parenteral
• 8.4. Topical

9. Acute Bacterial Skin & Skin Structure Infection Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Hospital Pharmacies
• 9.3. Online Pharmacies
• 9.4. Retail Pharmacies

10. Americas Acute Bacterial Skin & Skin Structure Infection Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Acute Bacterial Skin & Skin Structure Infection Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Acute Bacterial Skin & Skin Structure Infection Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbvie, Inc.
• 2. Accord Healthcare Limited
• 3. Amneal Pharmaceuticals, Inc.
• 4. Aurobindo Pharma Limited
• 5. Basilea Pharmaceutica Ltd
• 6. BiVictriX Therapeutics PLC
• 7. Cadila Pharmaceuticals Limited
• 8. Cumberland Pharmaceuticals Inc.
• 9. Debiopharm SA
• 10. Destiny Pharma PLC
• 11. Fresenius SE & Co. KGaA
• 12. GlaxoSmithKline PLC
• 13. Glenmark Pharmaceuticals Limited
• 14. Innovation Pharmaceuticals Inc.
• 15. Intas Pharmaceuticals Ltd.
• 16. KBP Biosciences Co., Ltd.
• 17. Melinta Therapeutics, LLC
• 18. Merck & Co, Inc
• 19. MicuRx Pharmaceuticals, Inc.
• 20. Novartis International AG
• 21. Paratek Pharmaceuticals, Inc.
• 22. Pfizer Inc.
• 23. Sun Pharmaceutical Industries Limited
• 24. Teva Pharmaceutical Industries Ltd.